Neuraxpharm Group, a leader in Central Nervous System (CNS) disorders, has partnered with Spanish start-up mjn-neuro to launch EPISERAS®—a pioneering digital health solution designed to predict epileptic seizures in real time. This innovative wearable technology aims to enhance patient-centric care for individuals with drug-resistant epilepsy, offering actionable insights that improve safety and reduce accident risks. The EPISERAS® system features a mobile app that visualizes seizure risk levels, supporting patients, caregivers, and healthcare professionals. Approved under Europe’s CE Mark (Class IIa medical) and UKCA regulations, EPISERAS® represents a shift for Neuraxpharm beyond traditional pharmaceuticals into holistic CNS care solutions, combining medication with advanced digital tools. Dr. Jörg-Thomas Dierks of Neuraxpharm emphasizes the commitment to enhancing patient autonomy and quality of life. David Blánquez of mjn-neuro highlights the extensive research backing this breakthrough. The European market launch is poised to reshape epilepsy treatment and improve patient outcomes significantly.
Source link
Share
Read more